Ultragenyx Pharma (RARE) holder FMR discloses 3.5% ownership stake

Rhea-AI Filing Summary

FMR LLC and Abigail P. Johnson filed an amended Schedule 13G reporting a passive ownership stake in Ultragenyx Pharma Inc.3.5% of the outstanding common stock as of the event date of 12/31/2025.

FMR LLC has sole voting power over 3,279,798 shares and sole dispositive power over 3,347,890.21 shares. Abigail P. Johnson has sole dispositive power over the same 3,347,890.21 shares but no voting power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Ultragenyx, with control-related activities limited to those connected to a nomination under Rule 14a-11.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ULTRAGENYX PHARMA INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

90400D108

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 90400D108

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,279,798.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,347,890.21
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,347,890.21

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 90400D108

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,347,890.21
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,347,890.21

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ULTRAGENYX PHARMA INC
(b)	Address of issuer's principal executive offices: 60 LEVERONI COURT,Novato,CA,USA,94949
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 90400D108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3347890.21
(b)	Percent of class: 3.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 3347890.21
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ULTRAGENYX PHARMA INC. No one other person's interest in the COMMON STOCK of ULTRAGENYX PHARMA INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	02/04/2026

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	02/04/2026

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

What does the Schedule 13G/A filing for Ultragenyx Pharma (RARE) report?

The filing reports a passive ownership stake in Ultragenyx Pharma common stock. FMR LLC and Abigail P. Johnson jointly report beneficial ownership of 3,347,890.21 shares, representing 3.5% of the company’s outstanding common stock as of the event date of December 31, 2025.

How many Ultragenyx Pharma (RARE) shares does FMR LLC beneficially own?

FMR LLC reports beneficial ownership of 3,347,890.21 Ultragenyx Pharma common shares. It has sole voting power over 3,279,798 shares and sole dispositive power over 3,347,890.21 shares, indicating it can decide how these shares are voted and whether they are sold.

What percentage of Ultragenyx Pharma (RARE) does FMR LLC and Abigail P. Johnson hold?

They collectively report beneficial ownership of 3.5% of Ultragenyx Pharma’s common stock. This percentage keeps the position below the 5% threshold while still representing a meaningful institutional stake disclosed under Schedule 13G’s beneficial ownership reporting rules.

Is FMR LLC’s stake in Ultragenyx Pharma (RARE) considered passive or activist?

The stake is characterized as passive. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ultragenyx, except for activities tied solely to a nomination under Rule 14a-11.

Does any single other investor hold more than 5% of Ultragenyx Pharma (RARE) through FMR accounts?

No single other investor exceeds 5%. The filing notes one or more other persons may receive dividends or sale proceeds from Ultragenyx common stock, but confirms that no one other person’s interest is more than five percent of the total outstanding common stock.

What role does Abigail P. Johnson have in the Ultragenyx Pharma (RARE) ownership disclosure?

Abigail P. Johnson is a separate reporting person with sole dispositive power over 3,347,890.21 shares, but no voting power. Her interest is reported alongside FMR LLC, reflecting control or oversight of entities that beneficially own Ultragenyx Pharma common stock disclosed in this Schedule 13G/A.